Telomir Pharmaceuticals (NASDAQ: TELO) has announced new research findings from The Ohio State University College of Veterinary Medicine showing that its lead compound, Telomir-Zn, produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, conducted under the direction of Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. These results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma as a model for human disease.
The significance of this announcement lies in its implications for both veterinary and human oncology. Osteosarcoma is an aggressive bone cancer that affects both dogs and humans, and naturally occurring canine osteosarcoma shares many clinical and molecular features with the human disease. By demonstrating comparable growth inhibition in both species' cell lines, Telomir-Zn may offer a unique opportunity to accelerate drug development through a "One Health" approach, where canine patients can serve as a translational bridge to human trials. This could potentially reduce the time and cost of bringing new therapies to market.
Telomir is in discussions with The Ohio State University College of Veterinary Medicine and is assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma. If successful, this could position Telomir-Zn as a first-in-class therapeutic for a cancer with limited treatment options.
However, the company said its immediate focus remains its triple-negative breast cancer program, which is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic triple-negative breast cancer (TNBC). Telomir-Zn is designed to modulate intracellular metal homeostasis and epigenetic regulation, targeting epigenetic and metabolic pathways implicated in cancer. The company is a clinical-stage biotechnology firm developing small-molecule therapeutics.
For investors, the osteosarcoma findings represent an additional potential indication for Telomir-Zn, expanding its pipeline beyond TNBC. While the TNBC program remains the priority, the osteosarcoma research highlights the versatility of the compound and its potential to address multiple cancer types. The news may also draw attention to the broader field of comparative oncology, where pet dogs with spontaneous cancers can inform human drug development.
To view the full press release, visit https://nnw.fm/laeGH. The latest news and updates relating to TELO are available in the company’s newsroom at https://nnw.fm/TELO. For more information about NetworkNewsWire, visit https://www.NetworkNewsWire.com.
